Search Result
Results for "
Selective COX-2 inhibitor
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
35
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-14445
-
COX-2 inhibitor V
|
COX
|
Inflammation/Immunology
|
FK 3311 (COX-2 Inhibitor V) is a selective inhibitor of COX-2 with antiinflammatory agent.
|
-
-
- HY-138128
-
-
-
- HY-162173
-
|
COX
|
Inflammation/Immunology
|
WYZ90 ((compound 6a) is a potent and selective COX-2 inhibitor with IC50 values of 75, 5734, 19940 nM for COX-2, COX-1 and DPPH, respectively. WYZ90 shows antioxidant and analgesic activity .
|
-
-
- HY-U00239
-
-
-
- HY-116610
-
|
COX
|
Inflammation/Immunology
|
L 748780 (compound 2) is a selectivity COX-2 inhibitor with the IC50 values of 0.5 μM and > 100 μM for COX-2 and COX-1, respectively .
|
-
-
- HY-115936
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-9 (compound 7a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 10.17 uM. COX-2-IN-9 has higher COX-2 selectivity than Celecoxib. COX-2-IN-9 shows good in vivo anti-inflammatory and low ulcerogenic activity .
|
-
-
- HY-115934
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-7 (compound 4a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-7 has higher COX-2 selectivity than Celecoxib. COX-2-IN-7 shows good in vivo anti-inflammatory and low ulcerogenic activity .
|
-
-
- HY-115935
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-8 (compound 6a) is a potent, selective, and orally active inhibitor of COX-2 with an IC50 of 6.585 uM. COX-2-IN-8 has higher COX-2 selectivity than Celecoxib. COX-2-IN-8 shows good in vivo anti-inflammatory and low ulcerogenic activity .
|
-
-
- HY-U00083
-
ZK 38997; CGP 28238
|
COX
|
Inflammation/Immunology
|
Flosulide is a potent and selective COX-2 inhibitor, used for the treatment for inflammatory diseases.
|
-
-
- HY-N11880
-
|
COX
|
Cancer
|
2-O-Sinapoyl makisterone A (compound 2), a sinapinic acid-ecdysterone hybrid, is a selective inhibitor of COX-2. 2-O-Sinapoyl makisterone A significantly inhibits the expression of COX-2 protein .
|
-
-
- HY-149299
-
|
COX
|
Inflammation/Immunology
|
PYZ18 is a selective COX-2 inhibitor with an IC50 of 7.07 μM. PYZ18 is the best lead compound for COX-2 inhibitors. PYZ18 has anti-inflammatory and other biological properties .
|
-
-
- HY-115866
-
|
COX
|
Cancer
|
COX-2-IN-6 (compound 10) is an orally active, gut-restricted and selective cyclooxygenase-2 (COX-2) inhibitor for colorectal Chemoprevention of cancer. COX-2-IN-6 selectively targets COX-2 with an IC50 of 0.84 μM and a Ki of 69 nM. COX-2-IN-6 also inhibits COX-2-driven PGE2 synthesis with an IC50 of 0.60 μM .
|
-
-
- HY-14398
-
SC 58635
|
COX
|
Inflammation/Immunology
Cancer
|
Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
|
-
-
- HY-150553
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-28 is a potent and selective COX-2 inhibitor with IC50 values of 0.054, 2.14, 13.21 µM for COX-2, 15-LOX, COX-1,respectively .
|
-
-
- HY-15762
-
-
-
- HY-147961
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-23 (compound 9a) is a selective COX-2 inhibitor with IC50 values of 0.28 and 20.14 μM for COX-2 and COX-1. COX-2-IN-23 has anti-inflammatory activity and low ulcerogenic activity.
|
-
-
- HY-U00022
-
-
-
- HY-D0053
-
6-Carboxy-X-rhodamine
|
Fluorescent Dye
|
Others
|
6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2 .
|
-
-
- HY-17357
-
-
-
- HY-U00146
-
-
-
- HY-17357S
-
AHR-9434-d5; AL-6515-d5
|
COX
|
Others
|
Nepafenac-d5 is the deuterium labeled Nepafenac, which is a selective COX-2 inhibitor.
|
-
-
- HY-150721
-
-
-
- HY-150551
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-27 is a potent and selective COX-2 inhibitor with IC50 values of 13.22, 0.045, 1.67 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-27 shows anti-inflammatory activity .
|
-
-
- HY-118078
-
|
COX
|
Inflammation/Immunology
|
Robenacoxib is a nonsteroidal anti-inflammatory and analgesic agent. Robenacoxib is a selective COX-2 inhibitor .
|
-
-
- HY-120232
-
-
-
- HY-156254
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-35 (compound 7) is a selective COX-2 inhibitor with an IC50 of 4.37 nM. COX-2-IN-35 has anti-inflammatory activity .
|
-
-
- HY-14670
-
ML 1785713
|
COX
|
Inflammation/Immunology
|
Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM). Firocoxib has anti-inflammatory effects .
|
-
-
- HY-145988
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-11 (compound 7b2) is a potent and selective inhibitor of COX-2. COX-2-IN-11 has the potential for the research of inflammation diseases .
|
-
-
- HY-U00129
-
-
-
- HY-161994
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-47 (compound 6c ) is a selective COX-2 inhibitor with IC50 value of 0.03 μM. COX-2-IN-47 has antiedema activity .
|
-
-
- HY-161147
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-37 (compound 11) is a potent and selective COX-2 inhibitor. COX-2-IN-37 has strong antioxidant activity with an IC50 of 33.0 μg/mL .
|
-
-
- HY-17372
-
MK 966
|
COX
|
Inflammation/Immunology
Cancer
|
Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).
|
-
-
- HY-15321
-
MK-0663; L-791456
|
COX
|
Inflammation/Immunology
Cancer
|
Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
|
-
-
- HY-134234
-
|
COX
|
Others
|
Celecoxib carboxylic acid is a metabolite of celecoxib (HY-14398). Celecoxib is a selective COX-2 inhibitor with an IC50 of 40 nM .
|
-
-
- HY-114795
-
|
COX
|
Inflammation/Immunology
|
Indomethacin heptyl ester is a selective COX-2 inhibitor with IC50 of 0.04 μM, exhibits anti-inflammatory activity .
|
-
-
- HY-101655
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-2 is a selective and inducible COX2 inhibitor with an IC50 of 0.24 μM. COX-2-IN-1 is an anti-inflammatory compound with anti-inflammatory and analgesic activities.
|
-
-
- HY-147809
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-20 (Compound 5d) is a selective and orally active COX-2 inhibitor with an IC50 of 17.9 nM. COX-2-IN-20 shows anti-inflammatory activity .
|
-
-
- HY-147692
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-14 (compound 2a) is a potent and selective COX-2 (cyclooxygenase-2) inhibitor. COX-2-IN-14 shows effective binding at the active site of COX-2 co-crystal. COX-2-IN-14 exhibits a high level of in vivo anti-inflammatory activity, reducing ear edema and myeloperoxidase (MPO) activity in mice .
|
-
-
- HY-150550
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-26 is a potent, selective and orally active COX-2 inhibitor with IC50 values of 10.61, 0.067, 1.96 µM for COX-1, COX-2, 15-LOX, respectively. COX-2-IN-26 shows anti-inflammatory activity. COX-2-IN-26 shows gastrointestinal safety profile .
|
-
-
- HY-U00197
-
JTE522; JTP19605; RWJ57504
|
COX
|
Inflammation/Immunology
|
Tilmacoxib (JTE522) is a highly selective, time-dependent and irreversible human COX-2 inhibitor with an IC50 of 85 nM in an enzyme assay.
|
-
-
- HY-149460
-
|
COX
|
Inflammation/Immunology
|
Harmaline analog (compound 3) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 0.145 μM .
|
-
-
- HY-147719
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-16 (compound 2b) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 102 µM. COX-2-IN-16 inhibits the NO production. COX-2-IN-16 shows anti-inflammatory activity .
|
-
-
- HY-15762S
-
-
-
- HY-162167
-
|
COX
|
Cardiovascular Disease
Neurological Disease
|
COX-1-IN-1 (compound 15a) is a selective inhibitor for cyclooxygenase (COX), with IC50s of 0.23 μM (COX-1) and >50 μM (COX-2), selective index (COX-2 IC50/COX-1 IC50) is 217. COX-1-IN-1 inhibits platelet aggregation .
|
-
-
- HY-147815
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-21 (Compound 5c) is a selective and orally active COX-2 inhibitor with an IC50 of 0.039 μM. COX-2-IN-21 shows promising anti-inflammatory potential .
|
-
-
- HY-161294
-
|
COX
|
Cancer
|
COX-2-IN-41 (compound 5e) is a selective inhibitor of COX-2 (IC50=1.74 μM). Compared with COX-1, the selectivity IC50 (COX-1)/IC50(COX-2) =16.32 .
|
-
-
- HY-15762R
-
SC 65872 (Standard)
|
Reference Standards
COX
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
Valdecoxib (Standard) is the analytical standard of Valdecoxib. This product is intended for research and analytical applications. Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
|
-
-
- HY-15321S
-
MK-0663-d4; L-791456-d4
|
COX
|
Others
|
Etoricoxib-d4 is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
|
-
-
- HY-B0335
-
GEA 6414
|
COX
|
Inflammation/Immunology
Cancer
|
Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
|
-
-
- HY-155133
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-34 (compound 8a) is a selective and orally active inhibitor of COX-2 , with an IC50 of 0.42 μM. COX-2-IN-34 has no gastric ulcer toxicity but has anti-inflammatory effects .
|
-
- HY-17372S
-
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Rofecoxib-d5 is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .
|
-
- HY-17372R
-
MK 966 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
Rofecoxib (Standard) is the analytical standard of Rofecoxib. This product is intended for research and analytical applications. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).
|
-
- HY-14670R
-
ML 1785713 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
|
Firocoxib (Standard) is the analytical standard of Firocoxib. This product is intended for research and analytical applications. Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM). Firocoxib has anti-inflammatory effects .
|
-
- HY-14398S1
-
SC 58635-d3
|
COX
|
Inflammation/Immunology
Cancer
|
Celecoxib-d3 is the deuterium labeled Celecoxib. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM .
|
-
- HY-14398S
-
SC 58635-d7
|
COX
|
Inflammation/Immunology
Cancer
|
Celecoxib-d7 is the deuterium labeled Celecoxib. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM .
|
-
- HY-B0559
-
BRL14777
|
COX
|
Inflammation/Immunology
Cancer
|
Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective COX-2 inhibitor, and is the proagent of the active metabolite 6MNA.
|
-
- HY-14670S
-
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
|
Firocoxib-d4 (ML 1785713-d4) is the deuterium labeled Firocoxib. Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM). Firocoxib has anti-inflammatory effects .
|
-
- HY-14398R
-
SC 58635 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
Celecoxib (Standard) is the analytical standard of Celecoxib. This product is intended for research and analytical applications. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
|
-
- HY-146371
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-13 (compound 13e) is a potent and selective inhibitor of COX-2 with an IC50 of 0.98 μM. COX-2-IN-13 is an anti-inflammatory agent. COX-2-IN-13 shows safety in-vivo acute toxicity study .
|
-
- HY-146370
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-12 (compound 3b) is a potent and selective inhibitor of COX-2 with an IC50 of 19.98 μM. COX-2-IN-12 is an anti-inflammatory agent. COX-2-IN-12 shows safety in-vivo acute toxicity study .
|
-
- HY-14398GL
-
SC 58635 (GMP Like)
|
COX
|
Inflammation/Immunology
|
Celecoxib (SC 58635) GMP Like is a GMP-class Celecoxib (HY-14398). Celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
|
-
- HY-15321S2
-
MK-0663-d3; L-791456-d3
|
COX
|
Inflammation/Immunology
|
Etoricoxib-d3 is the deuterium labeled Etoricoxib . Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood .
|
-
- HY-15321R
-
MK-0663 (Standard); L-791456 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
Etoricoxib (Standard) is the analytical standard of Etoricoxib. This product is intended for research and analytical applications. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
|
-
- HY-N3866
-
|
COX
|
Inflammation/Immunology
|
Esculentic acid is a selective COX-2 inhibitor and has anti-inflammatory effect. Esculentic acid is a pentacyclic triterpenoid that can be extracted from the Chinese herb Phytolacca esculenta .
|
-
- HY-168888
-
|
COX
|
Inflammation/Immunology
|
COX-2-IN-52 (Compound 5l) is an orally active and selective COX-2 inhibitor with an IC50 of 54 nM. COX-2-IN-52 can inhibit the release of NO in cells and has anti-inflammatory activity. COX-2-IN-52 has high gastrointestinal safety and can be used in the research of oral anti-inflammatory drugs .
|
-
- HY-15321S1
-
MK-0663-13C,d3; L-791456-13C,d3
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Etoricoxib- 13C,d3 is the 13C- and deuterium labeled Etoricoxib. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
|
-
- HY-B0335S1
-
GEA 6414-13C6
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Tolfenamic acid- 13C6 is the 13C6 labeled Tolfenamic acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
|
-
- HY-14654S
-
-
- HY-119304
-
-
- HY-118078R
-
|
COX
Reference Standards
|
Inflammation/Immunology
|
Robenacoxib (Standard) is the analytical standard of Robenacoxib. This product is intended for research and analytical applications. Robenacoxib is a nonsteroidal anti-inflammatory and analgesic agent. Robenacoxib is a selective COX-2 inhibitor .
|
-
- HY-B0335S
-
|
COX
|
Inflammation/Immunology
Cancer
|
Tolfenamic acid-d4 is the deuterium labeled Tolfenamic Acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1 .
|
-
- HY-B0335R
-
GEA 6414 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
Tolfenamic Acid (Standard) is the analytical standard of Tolfenamic Acid. This product is intended for research and analytical applications. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
|
-
- HY-W777079
-
SC 65872-13C2,15N
|
Isotope-Labeled Compounds
COX
Endogenous Metabolite
|
Cancer
|
Valdecoxib- 13C2, 15N (SC 65872- 13C2, 15N) is the 13C- and 15N-labeled Valdecoxib (HY-15762). Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
|
-
- HY-14783
-
-
- HY-134138
-
|
COX
|
Inflammation/Immunology
|
Indomethacin N-octyl amide (Compound 2) is a potent and selective COX-2 inhibitor with an IC50 of 40 nM. Indomethacin N-octyl amide shows >1000-fold selectivity against COX-1 (IC50 of 66 µM) .
|
-
- HY-14654S1
-
-
- HY-103387
-
|
COX
Apoptosis
|
Inflammation/Immunology
Cancer
|
DuP-697 is a member of the vicinal diaryl heterocycles and a potent, irreversible, selective and orally active COX-2 inhibitor (IC50 of 10 nM and 800 nM for human COX-2 and COX-1, respectively). DuP-697 exerts antiproliferative (IC50 of 42.8 nM), antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. DuP-697 inhibits prostaglandin synthesis and has anti-inflammatory, anticancer and antipyretic effects .
|
-
- HY-135081
-
N-4AIA
|
COX
|
Others
|
N-(4-acetamidophenyl)-indomethacin amide (N-4-AIA) is one of several aromatic amides of indomethacin reported to be potent and selective reversible inhibitors of COX-2.1 N-4-AIA inhibits human recombinant and ovine COX-2 with IC50 values of 0.12 and 0.625 μM, respectively. It is about 400 times less potent as an inhibitor of human recombinant COX-1 and 80 times less potent as an inhibitor of ovine COX-1 than ovine COX-2.
|
-
- HY-N0929
-
|
COX
Reactive Oxygen Species (ROS)
|
Cancer
|
Hexahydrocurcumin is one of the major metabolites of curcumin and a selective, orally active COX-2 inhibitor. Hexahydrocurcumin is inactive against COX-1. Hexahydrocurcumin has antioxidant, anticancer and anti-inflammatory activities .
|
-
- HY-B0559S
-
BRL14777-d3
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Nabumetone-d3 is the deuterium labeled Nabumetone. Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective COX-2 inhibitor, and is the proagent of the active metabolite 6MNA.
|
-
- HY-W015007
-
|
COX
|
Cardiovascular Disease
|
Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity . Metyrosine is a very effective agent for blood pressure control .
|
-
- HY-155997
-
|
COX
|
Inflammation/Immunology
|
Anti-inflammatory agent 56 (Compound 9) is a selective COX-2 inhibitor (IC50: 0.54 μM). Anti-inflammatory agent 56 has anti-oxidant and anti-inflammatory effects. Anti-inflammatory agent 56 inhibits oxidative stress induced cell death. Anti-inflammatory agent 56 inhibits oxidative stress and neuroinflammation by inhibiting Keap1, COX-2 and iNOS. Anti-inflammatory agent 56 has low acute toxicity in mice (LD50: 1000 mg/kg) .
|
-
- HY-134234R
-
|
COX
|
Others
|
Celecoxib carboxylic acid (Standard) is the analytical standard of Celecoxib carboxylic acid. This product is intended for research and analytical applications. Celecoxib carboxylic acid is a metabolite of celecoxib (HY-14398). Celecoxib is a selective COX-2 inhibitor with an IC50 of 40 nM .
|
-
- HY-19217
-
L-745337
|
COX
|
Inflammation/Immunology
|
Thioflosulide (L-745337) is a selective cyclooxygenase-2 (COX2) inhibitor, with an IC50 of 2.3 nM, and shows anti-inflammatory activity.
|
-
- HY-123639
-
N-(2-Phenylethyl)-indomethacin amide
|
COX
|
Inflammation/Immunology
Cancer
|
LM-4108 (N-(2-Phenylethyl)-indomethacin amide) is a selective and orally active COX-2 inhibitor with an IC50 of 0.06 μM for purified human COX-2. LM-4108 shows anti-inflammatory activity and may be effective in prevention of cancer. Half-lives for the disappearance of 10 μM LM-4108 in rat, human, and mouse liver microsomes were 11 min, 21 min, and 51 min, respectively .
|
-
- HY-118139
-
|
COX
|
Inflammation/Immunology
|
Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (COX-2) inhibitor (IC50=32 nM) with anti-inflammatory activities. Desmethyl Celecoxib is an analog of Celecoxib and with the optimal yield of 75% .
|
-
- HY-113083
-
APAP-glu
|
Drug Metabolite
Endogenous Metabolite
|
Others
|
Acetaminophen glucuronide (APAP-glu) is an inactive glucuronide metabolite of Acetaminophen (HY-66005) . Acetaminophen is a selective cyclooxygenase-2 (COX-2) inhibitor and a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
- HY-114200
-
BAP-909
|
COX
|
Inflammation/Immunology
|
Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect .
|
-
- HY-14398G
-
SC 58635
|
COX
|
Inflammation/Immunology
|
Celecoxib (GMP) is Celecoxib (HY-14398) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
|
-
- HY-B0559R
-
BRL14777 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
Nabumetone (Standard) is the analytical standard of Nabumetone. This product is intended for research and analytical applications. Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective COX-2 inhibitor, and is the proagent of the active metabolite 6MNA.
|
-
- HY-147911
-
|
PI3K
COX
|
Inflammation/Immunology
Cancer
|
COX-2/PI3K-IN-1 (compound 5d) is a potent PI3K inhibitor with IC50 value of 1.14 nM. COX-2/PI3K-IN-1 is a selective COX-2 inhibitor with Ki value of 3.24 nM. COX-2/PI3K-IN-1 has anti-inflammatory and anti-cancer properties.
|
-
- HY-119447
-
|
COX
|
Inflammation/Immunology
|
Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs .
|
-
- HY-66005S2
-
Paracetamol-d7; 4-Acetamidophenol-d7; 4'-Hydroxyacetanilide-d7
|
COX
Endogenous Metabolite
Histone Acetyltransferase
|
Inflammation/Immunology
|
Acetaminophen-d7 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor.
|
-
- HY-147912
-
|
PI3K
COX
|
Inflammation/Immunology
Cancer
|
COX-2/PI3K-IN-2 (compound 5f) is a potent PI3K inhibitor with IC50 value of 2.78 nM. COX-2/PI3K-IN-2 is a selective COX-2 inhibitor with Ki value of 3.02 nM. COX-2/PI3K-IN-2 shows anti-inflammatory and anti-cancer properties .
|
-
- HY-B0363
-
R805
|
COX
|
Inflammation/Immunology
Cancer
|
Nimesulide is a selective COX-2 inhibitor, with IC50s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC50 >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.
|
-
- HY-13507
-
COX-189
|
COX
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06?μM . Lumiracoxib acts as a nonselective NSAID with?anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
|
-
- HY-121537
-
|
COX
Akt
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities .
|
-
- HY-108259
-
|
PGE synthase
|
Inflammation/Immunology
|
HQL-79, a potent, selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, highly selectively inhibits the synthesis of PGD2, and acts as an anti-allergic agent, with a Kd of 0.8 μM and an IC50 of 6 μM. Shows no obvious effect on COX-1, COX-2, m-PGES, or L-PGDS .
|
-
- HY-134753
-
4-Amino-N-(4-trifluoromethylphenyl)benzamide
|
COX
|
Inflammation/Immunology
|
Teriflunomide impurity 3 (4-Amino-N-(4-trifluoromethylphenyl)benzamide) is a selective COX-1 inhibitor with an IC50 of 30 µM. Teriflunomide impurity 3 is less active against COX-2 (IC50>100 µM) .
|
-
- HY-66004
-
Diacetamate
|
Drug Intermediate
Bacterial
Parasite
|
Inflammation/Immunology
Cancer
|
4-Acetamidophenyl acetate is an impurity of Acetaminophen (HY-66005). 4-Acetamidophenyl acetate acts as an intermediate in the synthesis of Acetaminophen. Acetaminophen is a selective COX-2 inhibitor (IC50=25.8 μM), and is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
- HY-W013164
-
|
COX
|
Inflammation/Immunology
Cancer
|
SC-58125 is a potent and selective inhibitor of cyclooxygenase 2 (COX-2), with an IC50 of 0.04 μM. SC-58125 exhibits antitumor activity in vitro and in vivo. SC-58125 also can inhibit edema at the inflammatory site and has analgesic effect .
|
-
- HY-13913
-
|
COX
|
Inflammation/Immunology
Cancer
|
NS-398 is a non-steroidal an-inflammatory agent with analgesic and antipyretic effects, and selectively inhibits prostaglandin G/H synthase 2/cyclooxygenase 2 (COX-2) activity, with an IC50 of 3.8 μM, and has no effect on COX-1 at 100 μM.
|
-
- HY-66005S
-
Paracetamol-d4; 4-Acetamidophenol-d4; 4'-Hydroxyacetanilide-d4
|
COX
Histone Acetyltransferase
Endogenous Metabolite
|
Inflammation/Immunology
|
Acetaminophen-d4 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
- HY-66005S1
-
Paracetamol-d3; 4-Acetamidophenol-d3; 4'-Hydroxyacetanilide-d3
|
COX
Histone Acetyltransferase
Endogenous Metabolite
|
Inflammation/Immunology
|
Acetaminophen-d3 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
- HY-10439
-
|
PGE synthase
|
Inflammation/Immunology
|
HPGDS inhibitor 1 is a potent, selective and orally active Hematopoietic Prostaglandin D Synthase (HPGDS) inhibitor with an IC50s of 0.6 nM and 32 nM in enzyme and cellular assays, respectively. HPGDS inhibitor 1 does not inhibit human L-PGDS, mPGES, COX-1, COX-2, or 5-LOX .
|
-
- HY-17474A
-
SC 69124A
|
COX
|
Inflammation/Immunology
Cancer
|
Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
|
-
- HY-17474
-
SC 69124
|
COX
|
Inflammation/Immunology
Cancer
|
Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
|
-
- HY-W015007R
-
|
Reference Standards
COX
|
Cardiovascular Disease
|
Metyrosine (Standard) is the analytical standard of Metyrosine. This product is intended for research and analytical applications. Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity . Metyrosine is a very effective agent for blood pressure control .
|
-
- HY-N0929R
-
|
Reference Standards
COX
Reactive Oxygen Species (ROS)
|
Cancer
|
Hexahydrocurcumin (Standard) is the analytical standard of Hexahydrocurcumin. This product is intended for research and analytical applications. Hexahydrocurcumin is one of the major metabolites of curcumin and a selective, orally active COX-2 inhibitor. Hexahydrocurcumin is inactive against COX-1. Hexahydrocurcumin has antioxidant, anticancer and anti-inflammatory activities .
|
-
- HY-120824
-
|
COX
|
Inflammation/Immunology
|
Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active COX-1 inhibitor with an IC50 of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC50 of 447 nM). Mofezolac can relieve pain and has anti-inflammatory activities .
|
-
- HY-N0389
-
|
COX
Parasite
|
Inflammation/Immunology
|
Columbin is an orally active diterpenoid furanolactone from Calumbae radix, has anti-inflammatory and anti-trypanosomal effects. Columbin selectively inhibits COX-2 (EC50=53.1 μM) over COX-1 (EC50=327 μM) .
|
-
- HY-118139S
-
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
|
Celecoxib-d4 is the deuterium labeled Desmethyl Celecoxib. Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (COX-2) inhibitor (IC50=32 nM) with anti-inflammatory activities. Desmethyl Celecoxib is an?analog?of Celecoxib and with the optimal yield of 75% .
|
-
- HY-119447S
-
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
|
Mavacoxib-d4 is the deuterium labeled Mavacoxib. Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs .
|
-
- HY-W745860
-
|
Reactive Oxygen Species (ROS)
|
Cancer
|
Hexahydrocurcumin-d6 is the deuterium labeled Hexahydrocurcumin (HY-N0929). Hexahydrocurcumin is one of the major metabolites of curcumin and a selective, orally active COX-2 inhibitor. Hexahydrocurcumin is inactive against COX-1. Hexahydrocurcumin has antioxidant, anticancer and anti-inflammatory activities .
|
-
- HY-100516
-
UR-8880
|
COX
|
Inflammation/Immunology
|
Cimicoxib (CX) is an orally active potent and selective COX-2 (cyclo-oxygenase-2) inhibitor. Cimicoxib exhibits promising anti-inflammatory and analgesic activity. The PK parameters of Cimicoxib in dogs given precise (2 mg/kg) and approximate doses (1.95-2.5 mg/kg) are similar .
|
-
- HY-105028A
-
CP-66248 sodium
|
COX
|
Inflammation/Immunology
|
Tenidap is a non-steroidal anti-inflammatory active molecule and a selective inhibitor of COX-1, with IC50 values of 0.03 μM for COX-1 and 1.2 μM for COX-2. Tenidap exhibits anti-inflammatory and anti-rheumatic effects. Tenidap is a specific inhibitor of SLC26A3 .
|
-
- HY-66005
-
-
- HY-105028
-
CP-66248
|
COX
|
Inflammation/Immunology
|
Tenidap, a non-steroidal anti-inflammatory drug, is a selective COX-1 inhibitor, with IC50 values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively. Tenidap has anti-inflammatory and antirheumatic properties . Tenidap is also a specific SLC26A3 inhibitor .
|
-
- HY-114200R
-
BAP-909 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
|
Imrecoxib (Standard) is the analytical standard of Imrecoxib. This product is intended for research and analytical applications. Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 (COX-2) inhibitor with an IC50 value of 18 nM, it also inhibits COX1- activity with an IC50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect .
|
-
- HY-66005R
-
Paracetamol (Standard); 4-Acetamidophenol (Standard); 4'-Hydroxyacetanilide (Standard)
|
Reference Standards
COX
Histone Acetyltransferase
Endogenous Metabolite
Bacterial
Parasite
|
Inflammation/Immunology
Cancer
|
Acetaminophen (Standard) is the analytical standard of Acetaminophen. This product is intended for research and analytical applications. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
- HY-B0075S
-
-
- HY-119447R
-
|
COX
|
Inflammation/Immunology
|
Mavacoxib (Standard) is the analytical standard of Mavacoxib. This product is intended for research and analytical applications. Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs .
|
-
- HY-101546A
-
(+)-Cavidine
|
COX
|
Inflammation/Immunology
|
Cavidine ((+)-Cavidine) is a selective COX-2 inhibitor which possesses anti-inflammatory activity. Cavidine can be used for the research of skin injuries, hepatitis, cholecystitis, and scabies. Cavidine ameliorates LPS (HY-D1056)-induced acute lung injury via NF-κB signaling pathway .
|
-
- HY-66005S4
-
Paracetamol-13C2,15N; 4-Acetamidophenol-13C2,15N; 4'-Hydroxyacetanilide-13C2,15N
|
COX
Bacterial
Histone Acetyltransferase
Parasite
Endogenous Metabolite
|
Inflammation/Immunology
|
Acetaminophen- 13C2, 15N is the 13C and 15N labeled Acetaminophen . Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM;is a widely used antipyretic and analgesic agent . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
- HY-113083R
-
APAP-glu (Standard)
|
Reference Standards
Drug Metabolite
Endogenous Metabolite
|
Others
|
Acetaminophen glucuronide (Standard) is the analytical standard of Acetaminophen glucuronide. This product is intended for research and analytical applications. Acetaminophen glucuronide (APAP-glu) is an inactive glucuronide metabolite of Acetaminophen (HY-66005) . Acetaminophen is a selective cyclooxygenase-2 (COX-2) inhibitor and a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
- HY-121537R
-
|
COX
Akt
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
CAY10404 (Standard) is the analytical standard of CAY10404. This product is intended for research and analytical applications. CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities .
|
-
- HY-B0084
-
STS 557
|
Progesterone Receptor
|
Endocrinology
|
Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE2 synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .
|
-
- HY-13507R
-
COX-189 (Standard)
|
Reference Standards
COX
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Lumiracoxib (Standard) is the analytical standard of Lumiracoxib. This product is intended for research and analytical applications. Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM . Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research .
|
-
- HY-B0363R
-
R805 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
Nimesulide (Standard) is the analytical standard of Nimesulide. This product is intended for research and analytical applications. Nimesulide is a selective COX-2 inhibitor, with IC50s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC50 >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.
|
-
- HY-B0363S
-
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
|
Nimesulide-d5 is a deuterium labeled Nimesulide. Nimesulide is a selective COX-2 inhibitor, with IC50s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC50 >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties .
|
-
- HY-N1312
-
-
- HY-W015007S
-
|
COX
|
Cardiovascular Disease
|
Metyrosine- 13C9, 15N,d7 is the deuterium, 13C-, and 15-labeled Metyrosine. Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity . Metyrosine is a very effective agent for blood pressure control .
|
-
- HY-17474S
-
SC 69124-d3
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
|
-
- HY-105028S
-
CP-66248-d3
|
COX
|
Inflammation/Immunology
|
Tenidap-d3 is the deuterium labeled Tenidap. Tenidap, a non-steroidal anti-inflammatory drug, is a selective COX-1 inhibitor, with IC50 values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively. Tenidap has anti-inflammatory and antirheumatic properties . Tenidap is also a specific SLC26A3 inhibitor .
|
-
- HY-N0389R
-
|
Reference Standards
COX
Parasite
|
Inflammation/Immunology
|
Columbin (Standard) is the analytical standard of Columbin. This product is intended for research and analytical applications. Columbin is an orally active diterpenoid furanolactone from Calumbae radix, has anti-inflammatory and anti-trypanosomal effects. Columbin selectively inhibits COX-2 (EC50=53.1 μM) over COX-1 (EC50=327 μM) .
|
-
- HY-B0363S1
-
R805-13C6
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Nimesulide- 13C6 (R805- 13C6) is 13C labeled Nimesulide. Nimesulide is a selective COX-2 inhibitor, with IC50s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC50 >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.
|
-
- HY-17474AR
-
SC 69124A (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
Parecoxib (Sodium) (Standard) is the analytical standard of Parecoxib (Sodium). This product is intended for research and analytical applications. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
|
-
- HY-17474AS
-
SC 69124A-d5
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Parecoxib-d5 sodium is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo .
|
-
- HY-66005S3
-
-
- HY-17474R
-
SC 69124 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
Cancer
|
Parecoxib (Standard) is the analytical standard of Parecoxib. This product is intended for research and analytical applications. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
|
-
- HY-100516R
-
UR-8880 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
|
Cimicoxib (Standard) is the analytical standard of Cimicoxib. This product is intended for research and analytical applications. Cimicoxib (CX) is an orally active potent and selective COX-2 (cyclo-oxygenase-2) inhibitor. Cimicoxib exhibits promising anti-inflammatory and analgesic activity. The PK parameters of Cimicoxib in dogs given precise (2 mg/kg) and approximate doses (1.95-2.5 mg/kg) are similar .
|
-
- HY-105028R
-
CP-66248 (Standard)
|
Reference Standards
COX
|
Inflammation/Immunology
|
Tenidap (Standard) is the analytical standard of Tenidap. This product is intended for research and analytical applications. Tenidap, a non-steroidal anti-inflammatory drug, is a selective COX-1 inhibitor, with IC50 values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively. Tenidap has anti-inflammatory and antirheumatic properties . Tenidap is also a specific SLC26A3 inhibitor .
|
-
- HY-66004R
-
Diacetamate (Standard)
|
Reference Standards
Drug Intermediate
Bacterial
Parasite
|
Inflammation/Immunology
Cancer
|
4-Acetamidophenyl acetate (Standard) is the analytical standard of 4-Acetamidophenyl acetate (HY-66004). This product is intended for research and analytical applications. 4-Acetamidophenyl acetate is an impurity of Acetaminophen (HY-66005). 4-Acetamidophenyl acetate acts as an intermediate in the synthesis of Acetaminophen. Acetaminophen is a selective COX-2 inhibitor (IC50=25.8 μM), and is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
- HY-17474S1
-
SC 69124-d5
|
Isotope-Labeled Compounds
COX
|
Inflammation/Immunology
Cancer
|
Parecoxib-d5 (SC 69124-d5) is deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
|
-
- HY-B0084R
-
STS 557 (Standard)
|
Reference Standards
Progesterone Receptor
|
Endocrinology
|
Dienogest (Standard) is the analytical standard of Dienogest. This product is intended for research and analytical applications. Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE2 synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .
|
-
- HY-173485
-
|
SARS-CoV
COX
|
Infection
Inflammation/Immunology
|
SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor of COX-2 and SARS-CoV-2 M pro (IC50 values are 9.66 μM and 13.24 μM, respectively). SARS-CoV-2 Mpro-IN-41 also has a certain inhibitory activity against COX-1 (IC50: 46.11 μM). SARS-CoV-2 Mpro-IN-41 can significantly inhibit the expression of inflammatory-related cytokines (such as TNF-α, IL-6, IL-1β) and exert anti-inflammatory effects. SARS-CoV-2 Mpro-IN-41 exerts anti-inflammatory and antiviral effects by selectively inhibiting COX-2 and SARS-CoV-2 M pro. SARS-CoV-2 Mpro-IN-41 can be used for anti-inflammatory and anti-coronavirus research .
|
-
- HY-B0075
-
Melatonin
Maximum Cited Publications
99 Publications Verification
N-Acetyl-5-methoxytryptamine
|
Melatonin Receptor
Autophagy
Mitophagy
Endogenous Metabolite
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties . Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation . Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress .
|
-
- HY-N0396
-
|
COX
NO Synthase
|
Inflammation/Immunology
Cancer
|
Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ).
|
-
- HY-12383S
-
|
Isotope-Labeled Compounds
COX
|
Neurological Disease
Inflammation/Immunology
|
Pelubiprofen- 13C,d3 is the 13C- and deuterium labeled Pelubiprofen. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects .
|
-
- HY-155780
-
|
COX
|
Inflammation/Immunology
|
Anti-inflammatory agent 52 (compound 7j) is an orally active selective COX-2 inhibitor. Anti-inflammatory agent 52 has anti-HT29 transfer activity, which leads to periodic arrest in G2/M phase. Anti-inflammatory agent 52 has safety, moderate ability to suppress inflammation. Anti-inflammatory agent 52 has a rare property of suppressing the development of tumor in mouse model, showing anti-cancer activity .
|
-
- HY-155781
-
|
COX
|
Inflammation/Immunology
|
Anti-inflammatory agent 53 (compound 7c) is an orally active selective COX-2 inhibitor. Anti-inflammatory agent 52 has anti-HT29 transfer activity, which leads to periodic arrest in S phase and G2/M phase. Anti-inflammatory agent 52 has safety, moderate ability to suppress inflammation. Anti-inflammatory agent 52 has a rare property of suppressing the development of tumor in mouse model, showing anti-cancer activity .
|
-
- HY-111310
-
ML351
1 Publications Verification
|
Lipoxygenase
|
Neurological Disease
Metabolic Disease
|
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC50 of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .
|
-
- HY-B0075S1
-
-
- HY-Z7640
-
|
COX
|
Inflammation/Immunology
|
4-Desmethyl-2-methyl celecoxib (Compound 1g) is an orally active and selective Cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 0.069 μM. 4-Desmethyl-2-methyl celecoxib shows anti-inflammatory, analgesic, and antipyretic activities. 4-Desmethyl-2-methyl celecoxib can reduces the synthesis of prostaglandins. 4-Desmethyl-2-methyl celecoxib is promising for research of inflammatory diseases and pain-related diseases, such as rheumatoid arthritis and osteoarthritis .
|
-
- HY-113027R
-
|
Reference Standards
Endogenous Metabolite
|
Others
|
Melatonin (Standard) is the analytical standard of Melatonin. This product is intended for research and analytical applications. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties . Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation . Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress .
|
-
- HY-B0075S2
-
-
- HY-N0396R
-
|
Reference Standards
COX
NO Synthase
|
Inflammation/Immunology
|
Harpagoside (Standard) is the analytical standard of Harpagoside. This product is intended for research and analytical applications. Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ) .
|
-
- HY-B0075R
-
N-Acetyl-5-methoxytryptamine (standard); Melatonin
|
Reference Standards
Melatonin Receptor
Autophagy
Mitophagy
Endogenous Metabolite
Apoptosis
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Melatonin (Standard) is the analytical standard of Melatonin. This product is intended for research and analytical applications. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties . Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation . Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress .
|
-
- HY-118119
-
|
PGE synthase
|
Cancer
|
CAY10526 is a specific microsomal PGE2 synthase-1 (mPGES1) inhibitor. CAY10526 inhibits PGE2 production through the selective modulation of mPGES1 expression but does not affect COX-2. CAY10526 significantly suppresses tumor growth and increases apoptosis in melanoma xenografts. CAY10526 reduces BCL-2 and BCL-XL (anti-apoptotic) protein levels and increases BAX and BAK (pro-apoptotic) as well as cleaved caspase 3 levels. CAY10526 inhibits cell viability (IC50<5 μM) in three melanoma cell lines expressing mPGES1 .
|
-
- HY-W251428
-
Egg PG
|
Biochemical Assay Reagents
|
Others
|
Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV) .
|
-
- HY-B0084S4
-
STS 557-13C,15N,d4
|
Isotope-Labeled Compounds
Progesterone Receptor
|
Endocrinology
|
Dienogest-13C,15N,d4 (STS 557-13C,15N,d4) is the 13C, 15N and deuterium labeled isotope of Dienogest (HY-B0084). Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE2 synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .
|
-
- HY-19500
-
|
COX
|
Others
|
SC-75416 is a selective cyclooxygenase-2 inhibitor. Its pharmacokinetic/pharmacodynamic (PK/PD) model was used for development and clinical trial simulation to design a study protocol to verify its analgesic effect in a post-oral surgery pain model. The simulation results showed that 360 mg of SC-75416 may provide better pain relief than 400 mg of ibuprofen. The actual clinical trial results confirmed this hypothesis, and 360 mg of SC-75416 was indeed superior to 400 mg of ibuprofen in pain relief. The PK/PD model of SC-75416 showed good predictive performance and successfully predicted its clinical effect. These research results show that SC-75416, as a new selective COX-2 inhibitor, has potential clinical application value in the management of post-oral surgery pain.
|
-
- HY-114796
-
|
Lipoxygenase
|
Inflammation/Immunology
|
tHGA is a compound with anti-inflammatory activity and has the activity to inhibit soybean 15-LOX. tHGA showed significant inhibitory effects in experiments on human leukocytes, with an IC50 value of 0.42 μM, which is close to the effect of commonly used standard NDGA. tHGA concentration-dependently inhibits the synthesis of 5-LOX products, especially the cysteine leukotriene LTC(4), with an IC50 value of 1.80 μM. and showed no cytotoxicity. The anti-inflammatory effects of tHGA do not appear to be through redox or metal chelation mechanisms, as the compound was negative in these bioactivity tests. tHGA works through a dual LOX/COX inhibition mechanism and has higher selectivity for 5-LOX and COX-2, with an IC50 value of 0.40 μM .
|
-
- HY-19384
-
E 6087
|
COX
|
Inflammation/Immunology
|
Enflicoxib (E 6087) is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2 (COX-2).?Enflicoxib does not inhibit cyclooxygenase-1 (COX-1). E-6087 shows anti-inflammatory, analgesic and antipyretic activities in animal models .
|
-
- HY-106823
-
-
- HY-B1153A
-
Glafenin hydrochloride
|
COX
CFTR
Apoptosis
Endoplasmic Reticulum Oxidoreductase 1 (ERO1)
|
Metabolic Disease
Inflammation/Immunology
|
Glafenine (Glafenin) hydrochloride is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine hydrochloride exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine hydrochloride can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine hydrochloride can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
|
-
- HY-B1153
-
Glafenin
|
COX
CFTR
Apoptosis
Endoplasmic Reticulum Oxidoreductase 1 (ERO1)
|
Metabolic Disease
Inflammation/Immunology
|
Glafenine (Glafenin) is a non-selective, non-steroidal anti-inflammatory drug-based COX-1/COX-2 inhibitor. Glafenine exerts anti-inflammatory, anti-proliferative and anti-cell migration effects by inhibiting the arachidonic acid metabolic pathway and reducing prostaglandin synthesis. Glafenine can induce cell cycle arrest in vascular smooth muscle cells and endothelial cells and reduce the synthesis of the extracellular matrix protein Tenascin. Glafenine can be used in the research of inflammatory-related diseases, vascular restenosis and cystic fibrosis (CF) .
|
-
-
-
HY-L130
-
|
615 compounds
|
Non-steroidal anti-inflammatory drugs (NSAIDs) are members of a therapeutic drug class with potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. The most prominent NSAIDs are aspirin, ibuprofen, and naproxen.
The main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX), based on which NSAIDs can be classified into two types: non-selective and COX-2 selective. Most NSAIDs are non-selective and inhibit both COX-1 and COX-2 activity.
MCE offers a unique collection of 615 non-steroidal compounds with identified anti-inflammatory activity. MCE non-steroidal anti-inflammatory library is a useful tool for the study of anti-inflammatory drugs and pharmacology.
|
Cat. No. |
Product Name |
Type |
-
- HY-D0053
-
6-Carboxy-X-rhodamine
|
Oligonucleotide Labeling
|
6-ROX is a selective fluorescent probe and potential inhibitor of COX-2. 6-ROX binds to the active site of COX-2 and inhibits its conversion of arachidonic acid into prostaglandins. 6-ROX is often used in the field of optical imaging related to tumors and inflammation, and helps detect diseased tissues with high expression of COX-2 .
|
-
- HY-14398GL
-
SC 58635 (GMP Like)
|
Fluorescent Dye
|
Celecoxib (SC 58635) GMP Like is a GMP-class Celecoxib (HY-14398). Celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
|
-
- HY-14398G
-
SC 58635 (GMP)
|
Fluorescent Dye
|
Celecoxib (GMP) is Celecoxib (HY-14398) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
|
Cat. No. |
Product Name |
Type |
-
- HY-W251428
-
Egg PG
|
Drug Delivery
|
Phosphatidylglycerols (PG) is a selective inhibitor targeting the TLR4 accessory protein CD14/MD-2 complex, inhibiting LPS or virus (such as RSV)-mediated inflammatory signaling pathways through competitive binding. Phosphatidylglycerols directly bind to viral particles to block infection, inhibit COX-2 expression to reduce the release of inflammatory factors (IL-6, IL-8), and improve oxidative stress by regulating mitochondrial membrane phospholipid remodeling. Phosphatidylglycerols can be taken orally or by inhalation and can be used in the study of chronic inflammatory diseases (such as atherosclerosis) and respiratory viral infections (such as RSV) .
|
-
- HY-14398GL
-
SC 58635 (GMP Like)
|
Biochemical Assay Reagents
|
Celecoxib (SC 58635) GMP Like is a GMP-class Celecoxib (HY-14398). Celecoxib, a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
|
-
- HY-14398G
-
SC 58635 (GMP)
|
Biochemical Assay Reagents
|
Celecoxib (GMP) is Celecoxib (HY-14398) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM.
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17357S
-
|
Nepafenac-d5 is the deuterium labeled Nepafenac, which is a selective COX-2 inhibitor.
|
-
-
- HY-15321S
-
1 Publications Verification
|
Etoricoxib-d4 is a deuterium labeled Etoricoxib. Etoricoxib is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
|
-
-
- HY-17372S
-
|
Rofecoxib-d5 is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) .
|
-
-
- HY-14398S1
-
|
Celecoxib-d3 is the deuterium labeled Celecoxib. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM .
|
-
-
- HY-14398S
-
|
Celecoxib-d7 is the deuterium labeled Celecoxib. Celecoxib,a selective non-steroidal anti-inflammatory drug (NSAID), is a selective COX-2 inhibitor with an IC50 of 40 nM .
|
-
-
- HY-B0335S1
-
|
Tolfenamic acid- 13C6 is the 13C6 labeled Tolfenamic acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1.
|
-
-
- HY-15762S
-
|
Valdecoxib-d3 is the deuterium labeled Valdecoxib. Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain .
|
-
-
- HY-14670S
-
|
Firocoxib-d4 (ML 1785713-d4) is the deuterium labeled Firocoxib. Firocoxib (ML 1785713) is a potent, selective and orally active COX-2 inhibitor with an IC50 of 0.13 μM. Firocoxib shows 58-fold more selective for COX-2 than COX-1 (IC50 of 7.5 μM). Firocoxib has anti-inflammatory effects .
|
-
-
- HY-15321S2
-
|
Etoricoxib-d3 is the deuterium labeled Etoricoxib . Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood .
|
-
-
- HY-15321S1
-
|
Etoricoxib- 13C,d3 is the 13C- and deuterium labeled Etoricoxib. Etoricoxib (MK-0663) is a non steroidal anti-inflammatory agent, acting as a selective and orally active COX-2 inhibitor, with IC50s of 1.1 μM and 116 μM for COX-2 and COX-1 in human whole blood.
|
-
-
- HY-14654S
-
|
Aspirin-d3 is the deuterium labeled Aspirin. Aspirin is a non-selective and irreversible inhibitor of COX-1 and COX-2 with IC50s of 5 and 210 μg/mL.
|
-
-
- HY-B0335S
-
|
Tolfenamic acid-d4 is the deuterium labeled Tolfenamic Acid. Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory and anti-cancer agent, selectively inhibits COX-2, with an IC50 of 13.49 μM (3.53 μg/mL) in LPS-treated (COX-2) canine DH82 monocyte/macrophage cells, but shows no effect on COX-1 .
|
-
-
- HY-W777079
-
|
Valdecoxib- 13C2, 15N (SC 65872- 13C2, 15N) is the 13C- and 15N-labeled Valdecoxib (HY-15762). Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
|
-
-
- HY-14654S1
-
|
Aspirin-d4 is the deuterium labeled Aspirin. Aspirin is a non-selective and irreversible inhibitor of COX-1 and COX-2 with IC50s of 5 and 210 μg/mL .
|
-
-
- HY-B0559S
-
|
Nabumetone-d3 is the deuterium labeled Nabumetone. Nabumetone is an orally active non-acidic anti-inflammatory agent, acts as a potent and selective COX-2 inhibitor, and is the proagent of the active metabolite 6MNA.
|
-
-
- HY-66005S2
-
|
Acetaminophen-d7 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent. Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor.
|
-
-
- HY-66005S
-
|
Acetaminophen-d4 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
-
- HY-66005S1
-
|
Acetaminophen-d3 is the deuterium labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
-
- HY-118139S
-
|
Celecoxib-d4 is the deuterium labeled Desmethyl Celecoxib. Desmethyl Celecoxib (compound 3b) is a selective cyclooxygenase-2 (COX-2) inhibitor (IC50=32 nM) with anti-inflammatory activities. Desmethyl Celecoxib is an?analog?of Celecoxib and with the optimal yield of 75% .
|
-
-
- HY-119447S
-
|
Mavacoxib-d4 is the deuterium labeled Mavacoxib. Mavacoxib is a selective, oral long-acting cyclooxygenase-2 (COX-2) inhibitor and a long-acting non-steroidal anti-inflammatory drug (NSAID). Mavacoxib is used to treat pain and inflammation associated with degenerative joint disease in dogs .
|
-
-
- HY-W745860
-
|
Hexahydrocurcumin-d6 is the deuterium labeled Hexahydrocurcumin (HY-N0929). Hexahydrocurcumin is one of the major metabolites of curcumin and a selective, orally active COX-2 inhibitor. Hexahydrocurcumin is inactive against COX-1. Hexahydrocurcumin has antioxidant, anticancer and anti-inflammatory activities .
|
-
-
- HY-B0075S
-
|
Melatonin-d4 is deuterium labeled Melatonin. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Antioxidative and anti-inflammatory properties . Melatonin is a selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation .
|
-
-
- HY-66005S4
-
|
Acetaminophen- 13C2, 15N is the 13C and 15N labeled Acetaminophen . Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM;is a widely used antipyretic and analgesic agent . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
-
- HY-B0363S
-
|
Nimesulide-d5 is a deuterium labeled Nimesulide. Nimesulide is a selective COX-2 inhibitor, with IC50s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC50 >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties .
|
-
-
- HY-W015007S
-
|
Metyrosine- 13C9, 15N,d7 is the deuterium, 13C-, and 15-labeled Metyrosine. Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity . Metyrosine is a very effective agent for blood pressure control .
|
-
-
- HY-17474S
-
|
Parecoxib-d3 is the deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
|
-
-
- HY-105028S
-
|
Tenidap-d3 is the deuterium labeled Tenidap. Tenidap, a non-steroidal anti-inflammatory drug, is a selective COX-1 inhibitor, with IC50 values of 0.03 μM and 1.2 μM for COX-1 and COX-2, respectively. Tenidap has anti-inflammatory and antirheumatic properties . Tenidap is also a specific SLC26A3 inhibitor .
|
-
-
- HY-B0363S1
-
|
Nimesulide- 13C6 (R805- 13C6) is 13C labeled Nimesulide. Nimesulide is a selective COX-2 inhibitor, with IC50s of 70 nM-70 μM in a time-dependent manner, but it shows no effect on COX-1 (IC50 >100 μM). Nimesulide has potent anti-inflammatory, analgesic and antipyretic properties.
|
-
-
- HY-17474AS
-
|
Parecoxib-d5 sodium is the deuterium labeled Parecoxib sodium. Parecoxib Sodium (SC 69124A) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib Sodium can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo .
|
-
-
- HY-66005S3
-
|
Acetaminophen-13C6 (Paracetamol-13C6) is the 13C-labeled Acetaminophen. Acetaminophen (Paracetamol) is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 25.8 μM; is a widely used antipyretic and analgesic agent . Acetaminophen is a potent hepatic N-acetyltransferase 2 (NAT2) inhibitor .
|
-
-
- HY-17474S1
-
|
Parecoxib-d5 (SC 69124-d5) is deuterium labeled Parecoxib. Parecoxib (SC 69124) is a highly selective and orally active COX-2 inhibitor, the proagent of Valdecoxib (HY-15762). Parecoxib Sodium is a nonsteroidal anti-inflammatory agent (NSAID) and inhibits prostaglandin (PG) synthesis. Parecoxib can be used for the relief of acute postoperative pain and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis in vivo.
|
-
-
- HY-12383S
-
|
Pelubiprofen- 13C,d3 is the 13C- and deuterium labeled Pelubiprofen. Pelubiprofen, an orally active and non-steroidal anti-inflammatory drug, is a member of the 2-arylpropionic acid family and has relatively selective effects on COX-2 activity. Pelubiprofen inhibits COX activity and the transforming growth factor-β activated kinase 1-IκB kinase β-NF-κB pathway, and has significant anti-inflammatory and analgesic effects .
|
-
-
- HY-B0075S1
-
|
Melatonin-d3 is the deuterium labeled Melatonin. Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties . Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation . Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress .
|
-
-
- HY-B0075S2
-
|
Melatonin-d7 is the deuterium labeled Melatonin (HY-B0075). Melatonin is a hormone made by the pineal gland that can activates melatonin receptor. Melatonin plays a role in sleep and possesses important antioxidative and anti-inflammatory properties . Melatonin is a novel selective ATF-6 inhibitor and induces human hepatoma cell apoptosis through COX-2 downregulation . Melatonin attenuates palmitic acid-induced (HY-N0830) mouse granulosa cells apoptosis via endoplasmic reticulum stress .
|
-
-
- HY-B0084S4
-
|
Dienogest-13C,15N,d4 (STS 557-13C,15N,d4) is the 13C, 15N and deuterium labeled isotope of Dienogest (HY-B0084). Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE2 synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: